PRAN Split History

PRAN (PRAN) has 1 split in our PRAN split history database. The split for PRAN took place on March 24, 2016. This was a 1 for 6 reverse split, meaning for each 6 shares of PRAN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.

When a company such as PRAN conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the PRAN split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into PRAN shares, starting with a $10,000 purchase of PRAN, presented on a split-history-adjusted basis factoring in the complete PRAN split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	06/11/2013
End date:	04/08/2019
Start price/share:	$14.70
End price/share:	$2.06
Dividends collected/share:	$0.00
Total return:	-85.99%
Average Annual Total Return:	-28.63%
Starting investment:	$10,000.00
Ending investment:	$1,400.81
Years:	5.83

About PRAN

Alterity Therapeutics is a development stage medical biotechnology company based in Australia. Co. is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain and the eye as the aging process progresses, focusing on Alzheimer's disease, Huntington disease and Parkinson's disease and other movement disorders. Other potential applications for Co.'s therapies include neurodegenerative disorders, certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease) and a variety of orphan neurodegenerative disorders. According to our PRAN split history records, PRAN has had 1 split.